bivatuzumab mertansine (BIWI 1)
/ Boehringer Ingelheim, AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2014
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: Boehringer Ingelheim
New P1 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
1 to 1
Of
1
Go to page
1